Novartis AG
NVS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001114448
No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 1,632 institutions reported holding it in 13F filings for Q2 2026, worth $21.3B in total; Maverick Capital is the only superinvestor holding it.
Other share classesNVSEF
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +42 vs. previous quarter
- 1,632
- 13F valueReported value at the end of Q2 2026
- $21.3B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $54.5B
- +8.4% year over year
- Net income, FY2025
- $14.0B
- +17.0% year over year
- Free cash flow, FY2025
- $17.6B
- +8.3% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.52M
- Shares sold short
- Change
- −1.07M
- −19.2% vs. previous
- Days to cover
- 1.89
- At average daily volume
Superinvestors holding NVS, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Novartis AG on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Novartis AG insiders from Form 4, newest first.
No open-market purchases or sales by Novartis AG insiders are on file.
Top 10 13F holders, Q2 2026
See all 1,632 holdersThe largest institutional positions in Novartis AG at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Fisher Asset Management, LLC | 15,523,378 | $2.43B | 0.72% | +1,637,629+11.8% | Added |
| Morgan Stanley | 8,726,827 | $1.37B | 0.07% | +199,790+2.3% | Added |
| Dimensional Fund Advisors LP | 8,117,586 | $1.27B | 0.23% | +7,470+0.1% | Added |
| Primecap Management Co | 6,592,124 | $1.03B | 0.61% | −975,230−12.9% | Reduced |
| Loomis Sayles & Co L P | 5,239,309 | $821.1M | 1.03% | −186,791−3.4% | Reduced |
| Bank of America Corp | 4,909,938 | $769.5M | 0.05% | −52,856−1.1% | Reduced |
| Franklin Resources Inc | 3,251,281 | $509.5M | 0.11% | −158,663−4.7% | Reduced |
| BlackRock, Inc. | 3,047,988 | $477.7M | 0.01% | +98,228+3.3% | Added |
| Goldman Sachs Group Inc | 2,980,168 | $467.1M | 0.05% | −3,545,603−54.3% | Reduced |
| Northern Trust Corp | 2,792,745 | $437.7M | 0.05% | +6,517+0.2% | Added |
Holders of 5% or more of NVS
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Novartis AG.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| UBS Asset Management Americas Inc | 13G | 6.40%139.6M shares | New | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
Politician trades
All politician trades in NVS14 members of Congress reported 42 trades in Novartis AG since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 25, 2026 |  Kevin Hern House · OK | Sell | $15K-$50K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $15K-$50K |
| Jul 21, 2026 | Alan Armstrong Senate · OK | Buy | $1K-$15K |
| Nov 21, 2025 |  Lisa C. McClain House · MI | Sell | $1K-$15K |
| Nov 21, 2025 | Lisa C. McClain House · MI | Buy | $1K-$15K |
House · OK · Sep 25, 2026
Sell$15K-$50K
Senate · OK · Jul 21, 2026
Buy$15K-$50K
Senate · OK · Jul 21, 2026
Buy$1K-$15K
House · MI · Nov 21, 2025
Sell$1K-$15K
House · MI · Nov 21, 2025
Buy$1K-$15K